Tricyclic aminocyanopyridine inhibitors of mitogen activated protein kinase-activated protein kinase-2
Aminocyanopyridine compounds are described which are capable of inhibiting mitogen activated protein kinase-activated protein kinase-2. Pharmaceutical compositions and kits are also described, which include an anminocyanopyridine MK-2 inhibiting compound.